更新
3月31日 - ** 制药公司Corcept Therapeutics CORT.O股价飙升91.7%，创下104.73 美元的历史新高
** 股价最后上涨83.6%，报100.29美元
** CORT公司称， (link)，其治疗卵巢癌的实验性药物与化疗联合使用达到了后期试验的主要目标。
** 该公司称，该药物 relacorilant 与化疗药物纳布紫杉醇（nab-paclitaxel）联用后，铂类耐药卵巢癌患者的疾病进展风险比单独接受化疗的患者 降低了 30%。
** Canaccord Genuity 分析师 Edward Nash 预计，到 2036 年，relacorilant 的销售峰值将达到 13 亿美元。
** 铂类耐药卵巢癌是一种对铂类化疗无效的卵巢癌，铂类化疗通常被用作一线疗法。
** 包括本交易日的走势在内，CORT的股价在今年以来上涨了一倍多
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.